The story of Sifar Ilaclari began in 1966 when the chemist from Turin, Dr. Parodi, went to Istanbul to establish the pharmaceutical production for Lepetit S.p.A. Group, one of the most important Italian companies of the time, which discovered Rifampicin. When the Italian company ceased its local activity, Dr. Parodi founded Sifar Ilaclari to continue Lepetit's work as a representative in Turkey. In 1970, Ahmet Muderrisoglu, the son-in-law of Dr. Parodi, a pharmacist from a family of pharmacists, took over the management of Sifar.
Dr. Muderrisoglu, having worked on the application of GMP (Good Manufacturing Practices) processes at the German pharmaceutical company C.H. Boehringer Sohn Ingelheim, applied these processes to Sifar Ilaclari, making Sifar the first company in Turkey to apply GMP. Making quality and innovation the two principles of the company, Sifar Ilaclari's motto became "Sifar, the architect of quality in medicines".
The innovative approach of Sifar Ilaclari continued in the 1980s with the adoption of the latest developments in the field of bioavailability. Bioavailability indicates the level and the pace of a drug reaching the circulation system. Lepetit S.p.A., with its brochure entitled "The Bioavailability of Rifampicin", in April 1982 highlighted the importance of the concept of bioavailability, especially in the production of Rifampicin. As a manufacturer representing Lepetit, Sifar Ilaclari was the first company to introduce the concept of bioavailability into the Turkish pharmaceutical market.
At the beginning of the 21st century, due to developments in Turkey and in the world, Sifar Ilaclari decided to cease the production of pharmaceuticals and decided to head towards the food supplement market with the leadership of the third generation of the family, by Sinan Muderrisoglu. The mission of the company was set to introduce food supplements with pharmaceutical quality. In 2004, Sifar acquired the "NEW LIFE" food supplement brand, which was already present in the Turkish market. The production of all supplements was transferred to European manufacturers that were producing with GMP.
From 2005 to today, Sifar Ilaclari has introduced various innovative products with a high concentration of Omega-3 under the “New Life EFA” brand to the consumers of the Turkish market. Sifar is one of the first founding members of GOED (The Global Organization for EPA & DHA Omega-3s USA), which was founded in 2006 to ensure the worldwide production of reliable and high-quality fish oil. Furthermore, from 2009 to today, each series of EFA Omega-3 produced has marketed only after passing the IFOS (International Fish Oil Standards) control in “NUTRASOURCE DIAGNOSTIC” in Canada.
Sifar, with decades of experience in the pharmaceutical market, operates with the principle that the quality of a product starts from its raw materials. Ingredients are selected from suppliers which have high quality and effective compounds. Additionally, only fish or vegetarian gelatine is used in producing the softgel capsules. All products in capsules or tablets are presented in blister packs, to ensure the hygiene after each use.
The journey that the Turin chemist Dr. Parodi started in Istanbul in 1966, is now returning to Italy with the third generation of the family. The food supplement products of New Life, that have become leaders in many categories in the Turkish market, are now introduced to European consumers with the Sifar Nutra brand starting from 2021.